نتایج جستجو برای: idarubicin

تعداد نتایج: 767  

Journal: :Cancer research 1985
F Arcamone

The established efficacy of doxorubicin in the medical treatment of cancer is hampered by dose limiting side effects and lack of activity on major clinical tumors. The new derivative epirubicin (4'-epidoxorubicin) is already available clinically as a better tolerated drug, with confirmed efficacy on doxorubicin responsive diseases. Because of the different orientation of the 4'-hydroxyl, the co...

Journal: :Annals of oncology : official journal of the European Society for Medical Oncology 2010
A H Herbers T Feuth J P Donnelly N M Blijlevens

BACKGROUND Currently, objective tests are lacking that enable the extent and duration of intestinal mucosal damage induced by myeloablative chemotherapy to be determined. To address this problem, we explored a citrulline-based assessment score as this amino acid is a simple quantitative marker of intestinal failure. PATIENTS AND METHODS From March 2004 to June 2007, citrulline concentrations ...

Journal: :Clinical advances in hematology & oncology : H&O 2009
Alexander Pham Bahareh Bahadini Randa Alsabeh Amir Steinberg

A 32-year-old Hispanic male with a history of acute pro myelocytic leukemia (APL) in complete remission presented with increasing fatigue and mild dyspnea. His previous diagnosis of APL was made 2 years ago (Figure 1). Cytogenetic evaluation at the time of diagnosis demonstrated the presence of a reciprocal translocation between chromosomes 15 and 17, t(15;17), and the promyelocytic/retinoic ac...

2014
Mohamad Khawandanah Bradley Gehrs Shibo Li Jennifer Holter Chakrabarty Mohamad Cherry

Background. We hereby describe what we believe to be the first reported case of t (14; 15) (q32; q13) associated with acute myeloid leukemia (AML). Methods. PubMed, Embase, and OVID search engines were used to review the related literature and similar published cases. Case. A47-year-old female presented in December 2011 with AML (acute myelomonocytic leukemia) with normal cytogenetics; molecula...

Journal: :Blood 2002
Elihu H Estey Francis J Giles Miloslav Beran Susan O'Brien Sherry A Pierce Stefan H Faderl Jorge E Cortes Hagop M Kantarjian

We administered gemtuzumab ozogamycin ("mylotarg"; 9 mg/m(2) day 1 or 5) and all-trans retinoic acid (ATRA) to 19 patients with untreated acute promyelocytic leukemia (APL). There were 3 patients who also received idarubicin because of a white blood cell (WBC) count of more than 30 000/microL. In complete remission (CR), patients were to receive 8 courses of mylotarg (9 mg/m(2) every 4 to 5 wee...

2015
Dong Gui Hu Peter I. Mackenzie Lu Lu Robyn Meech Ross A. McKinnon

We recently reported induction ofUGT2B7 by its substrate epirubicin, a cytotoxic anthracycline anticancer drug, via activation of p53 and subsequent recruitment of p53 to the UGT2B7 promoter in hepatocellular carcinoma HepG2 cells. Using the same HepG2 model cell line, the present study assessed the possibility of a similar induction of UGT2B7 by several other cytotoxic drugs. We first demonstr...

Journal: :Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2011
Jonas Abrahamsson Erik Forestier Jesper Heldrup Kirsi Jahnukainen Olafur G Jónsson Birgitte Lausen Josefine Palle Bernward Zeller Henrik Hasle

PURPOSE To evaluate the early treatment response in children with acute myeloid leukemia (AML) using a response-guided induction strategy that includes idarubicin in the first course. PATIENTS AND METHODS All Nordic children with AML younger than 15 years (n = 151) were treated on the Nordic Society for Pediatric Hematology and Oncology (NOPHO) AML 2004 protocol. After the first course of ida...

2014
Ashish Narayan Masurekar Catriona A. Parker Milensu Shanyinde Anthony V. Moorman Jeremy P. Hancock Rosemary Sutton Philip J. Ancliff Mary Morgan Nicholas J. Goulden Chris Fraser Peter M. Hoogerbrugge Tamas Revesz Philip J. Darbyshire Shekhar Krishnan Sharon B. Love Vaskar Saha Maria R. Baer

UNLABELLED The outcomes of Central Nervous System (CNS) relapses in children with acute lymphoblastic leukaemia (ALL) treated in the ALL R3 trial, between January 2003 and March 2011 were analysed. Patients were risk stratified, to receive a matched donor allogeneic transplant or fractionated cranial irradiation with continued treatment for two years. A randomisation of Idarubicin with Mitoxant...

Journal: :Blood 2014
Michela Tassara Konstanze Döhner Peter Brossart Gerhard Held Katharina Götze Heinz-A Horst Mark Ringhoffer Claus-Henning Köhne Stephan Kremers Aruna Raghavachar Gerald Wulf Heinz Kirchen David Nachbaur Hans Günter Derigs Mohammed Wattad Elisabeth Koller Wolfram Brugger Axel Matzdorff Richard Greil Gerhard Heil Peter Paschka Verena I Gaidzik Martin Göttlicher Hartmut Döhner Richard F Schlenk

The outcome of patients with acute myeloid leukemia who are older than 60 years has remained poor because of unfavorable disease characteristics and patient-related factors. The randomized German-Austrian AML Study Group 06-04 protocol was designed on the basis of in vitro synergistic effects of valproic acid (VPA) and all-trans retinoic acid with chemotherapy. Between 2004 and 2006, 186 patien...

Journal: :Blood 1997
N J Ketley P D Allen S M Kelsey A C Newland

The relationship between differentiation of human myeloid cells and apoptosis remains unclear. Recent studies have shown that terminal differentiation need not necessarily lead to the apoptotic demise of myeloid cells, while other studies have shown that induction of differentiation is associated with increased resistance to apoptosis-inducing agents, such as chemotherapy and gamma-irradiation....

نمودار تعداد نتایج جستجو در هر سال

با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید